Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Accured Expenses (2016 - 2025)

Assembly Biosciences has reported Change in Accured Expenses over the past 11 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $1.2 million for Q4 2025, up 199.28% from a year ago — trailing twelve months through Dec 2025 was $114000.0 (down 89.8% YoY), and the annual figure for FY2025 was $114000.0, down 89.8%.
  • Change in Accured Expenses for Q4 2025 was $1.2 million at Assembly Biosciences, up from -$552000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ASMB hit a ceiling of $5.4 million in Q4 2021 and a floor of -$7.5 million in Q2 2021.
  • Median Change in Accured Expenses over the past 5 years was $444500.0 (2024), compared with a mean of -$79550.0.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 2222.96% in 2023 and later soared 742.8% in 2025.
  • Assembly Biosciences' Change in Accured Expenses stood at $5.4 million in 2021, then crashed by 69.89% to $1.6 million in 2022, then dropped by 27.32% to $1.2 million in 2023, then crashed by 65.02% to $417000.0 in 2024, then surged by 199.28% to $1.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were $1.2 million (Q4 2025), -$552000.0 (Q3 2025), and $4.0 million (Q2 2025) per Business Quant data.